Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab

PURPOSE: To assess the efficacy of intravitreal brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of recalcitrant cystoid macular edema associated with radiation maculopathy secondary to retinoblastoma which was suboptimally responsive to other intravitreal anti-vascular endothelial growth f...

Descripción completa

Detalles Bibliográficos
Autores principales: Corradetti, Giulia, Corvi, Federico, Juhn, Alexander, Sadda, SriniVas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595878/
https://www.ncbi.nlm.nih.gov/pubmed/33145457
http://dx.doi.org/10.1016/j.ajoc.2020.100981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595878/
https://www.ncbi.nlm.nih.gov/pubmed/33145457
http://dx.doi.org/10.1016/j.ajoc.2020.100981

Ejemplares similares